MCID: NRF003
MIFTS: 44

Neurofibrosarcoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Neurofibrosarcoma

MalaCards integrated aliases for Neurofibrosarcoma:

Name: Neurofibrosarcoma 12 76 53 29 13 55 6 44 15 73
Malignant Peripheral Nerve Sheath Tumor 73
Neurosarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3512
MeSH 44 D018319
SNOMED-CT 68 19897006 404037002
UMLS 73 C0206729

Summaries for Neurofibrosarcoma

MalaCards based summary : Neurofibrosarcoma, also known as malignant peripheral nerve sheath tumor, is related to malignant peripheral nerve sheath tumor and neurofibroma. An important gene associated with Neurofibrosarcoma is MXI1 (MAX Interactor 1, Dimerization Protein), and among its related pathways/superpathways is Glioblastoma Multiforme. The drugs Doxorubicin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A malignant peripheral nerve sheath tumor (MPNST) (also known as \"malignant schwannoma\",... more...

Related Diseases for Neurofibrosarcoma

Diseases related to Neurofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 malignant peripheral nerve sheath tumor 32.3 NF1 NF2
2 neurofibroma 30.2 NF1 NF2
3 neurofibromatosis, type iv, of riccardi 29.8 NF1 NF2
4 neuroma 29.5 NF1 NF2
5 childhood malignant schwannoma 10.9
6 adult malignant schwannoma 10.9
7 neurofibromatosis, familial spinal 10.2 NF1 NF2
8 plexiform schwannoma 10.2 NF1 NF2
9 immature cataract 10.2 NF1 NF2
10 plexiform neurofibroma 10.2 NF1 NF2
11 atypical neurofibroma 10.2 NF1 NF2
12 amyloid tumor 10.2 NF1 NF2
13 spinal meningioma 10.2 NF1 NF2
14 spinal canal and spinal cord meningioma 10.2 NF1 NF2
15 neurilemmomatosis 10.2 NF1 NF2
16 optic nerve neoplasm 10.1 NF1 NF2
17 acoustic neuroma 10.1 NF1 NF2
18 spinal cord ependymoma 10.1 NF1 NF2
19 cellular schwannoma 10.1 NF1 NF2
20 neurofibromatosis, type ii 10.1 NF1 NF2
21 sarcoma 10.1
22 neurilemmoma 10.1 NF1 NF2
23 organ system benign neoplasm 10.0 NF1 NF2
24 neurofibromatosis, type i 10.0
25 peripheral nervous system neoplasm 10.0 NF1 NF2
26 ependymoma 9.9 NF2 TP73
27 nervous system cancer 9.9 NF1 NF2
28 elephantiasis 9.9 INSRR NF1
29 mediastinitis 9.9
30 hypoglycemia 9.9
31 type i 9.9
32 autosomal genetic disease 9.8 NF1 NF2
33 spondyloarthropathy 1 9.7
34 ovarian cancer 9.7
35 pheochromocytoma 9.7
36 lymphoma, hodgkin, classic 9.7
37 myasthenia gravis 9.7
38 wilms tumor 5 9.7
39 wilms tumor 6 9.7
40 angiosarcoma 9.7
41 lymphoma 9.7
42 graves' disease 9.7
43 hyperinsulinemic hypoglycemia 9.7
44 prostatitis 9.7
45 leiomyosarcoma 9.7
46 cervicitis 9.7
47 thymoma 9.7
48 cerebritis 9.7
49 femoral neuropathy 9.7
50 spindle cell sarcoma 9.7

Graphical network of the top 20 diseases related to Neurofibrosarcoma:



Diseases related to Neurofibrosarcoma

Symptoms & Phenotypes for Neurofibrosarcoma

GenomeRNAi Phenotypes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.44 DCK
2 Decreased viability GR00221-A-1 9.44 DCK INSRR NF1
3 Decreased viability GR00221-A-2 9.44 DCK NF1
4 Decreased viability GR00221-A-4 9.44 DCK NF1
5 Decreased viability GR00240-S-1 9.44 DCK
6 Decreased viability GR00301-A 9.44 INSRR
7 Decreased viability GR00402-S-2 9.44 DCK INSRR NF1

MGI Mouse Phenotypes related to Neurofibrosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.65 TP73 DCK MXI1 NF1 NF2
2 immune system MP:0005387 9.55 NF2 TP73 DCK MXI1 NF1
3 neoplasm MP:0002006 9.26 TP73 MXI1 NF1 NF2
4 renal/urinary system MP:0005367 8.92 INSRR MXI1 NF1 NF2

Drugs & Therapeutics for Neurofibrosarcoma

Drugs for Neurofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
18
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
24 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
25 Nucleic Acid Synthesis Inhibitors Phase 3
26 Etoposide phosphate Phase 3,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1
29 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
30 Antirheumatic Agents Phase 3,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Serotonin Agents Phase 3
38 Serotonin Antagonists Phase 3
39 Gastrointestinal Agents Phase 3
40 Neurotransmitter Agents Phase 3
41 Histamine Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43 Dermatologic Agents Phase 3
44 Anti-Allergic Agents Phase 3
45 Antipruritics Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
19 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
20 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
21 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
22 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
23 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
24 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
25 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
27 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
28 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
29 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
35 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
36 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
37 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
38 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
39 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
40 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
41 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
42 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
43 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
44 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
45 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
46 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
47 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
48 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
49 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
50 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib

Search NIH Clinical Center for Neurofibrosarcoma

Cochrane evidence based reviews: neurofibrosarcoma

Genetic Tests for Neurofibrosarcoma

Genetic tests related to Neurofibrosarcoma:

# Genetic test Affiliating Genes
1 Neurofibrosarcoma 29

Anatomical Context for Neurofibrosarcoma

MalaCards organs/tissues related to Neurofibrosarcoma:

41
Bone, Lung, Kidney, Testis, Cervix, Prostate, Liver

Publications for Neurofibrosarcoma

Articles related to Neurofibrosarcoma:

(show top 50) (show all 735)
# Title Authors Year
1
Malignant peripheral nerve sheath tumor of the trigeminal nerve involving the middle and posterior cranial fossa. ( 29408426 )
2018
2
Malignant peripheral nerve sheath tumor: The need to get it right first time around. ( 29115724 )
2018
3
Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports. ( 29900032 )
2018
4
Case Report: Metastasis of a Trigeminal Malignant Peripheral Nerve Sheath Tumor to the Corpus Callosum. ( 29518229 )
2018
5
Atypical presentation of a primary cardiac malignant peripheral nerve sheath tumor. ( 29318408 )
2018
6
Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence. ( 29369179 )
2018
7
Case of an Intracranial Malignant Peripheral Nerve Sheath Tumor in the Setting of Pacer-dependent Heart Block. ( 29492148 )
2018
8
Immunohistochemical analysis of epigenetic factors to differentiate malignant peripheral nerve sheath tumor from benign neurofibroma in a patient with mosaic neurofibromatosis type 1: H3 lysine 27 trimethylation stain and enhancer of zeste homolog 2 stain. ( 29687471 )
2018
9
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
10
Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. ( 29974241 )
2018
11
Low- Grade Malignant Peripheral Nerve Sheath Tumor Mimicking a Schwannoma: The Role and Importance of Trimethylated H3K27M Staining. ( 29909207 )
2018
12
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
13
Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome. ( 29061454 )
2018
14
Retrobulbar malignant peripheral nerve sheath tumor in a golden retriever dog: A challenging diagnosis. ( 29606723 )
2018
15
CASE SERIES: Malignant Peripheral Nerve Sheath Tumor in the Course of the Mandibular Nerve. ( 29883816 )
2018
16
A case report of cervical neurofibrosarcoma: Clinical presentation, treatment and outcome. ( 29253810 )
2018
17
Supraclavicular Brachial Plexus Neurolysis for a Malignant Peripheral Nerve Sheath Tumor: A Case Report. ( 29894352 )
2018
18
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 29543881 )
2018
19
Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. ( 29332262 )
2018
20
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. ( 28752843 )
2017
21
Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography Masquerading as a Case of Sporadic Malignant Peripheral Nerve Sheath Tumor of Lower Extremity Presenting as Massive Lower Limb Edema. ( 29033684 )
2017
22
Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. ( 27706810 )
2017
23
Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. ( 28658406 )
2017
24
Radiation-Induced Glandular Malignant Peripheral Nerve Sheath Tumor. ( 28530162 )
2017
25
The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells. ( 28502478 )
2017
26
Rexin-G(Ar), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. ( 28588778 )
2017
27
Malignant Peripheral Nerve Sheath Tumor of the Femur: A Rare Diagnosis Supported by Complete Immunohistochemical Loss of H3K27me3. ( 28508686 )
2017
28
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. ( 29138703 )
2017
29
Metastatic Epithelioid Malignant Peripheral Nerve Sheath Tumor in a Known Case of Neurofibromatosis-1, Cytomorphological Appearance, and Critical Analysis of Immunohistochemistry. ( 29200699 )
2017
30
Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1. ( 28548697 )
2017
31
Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens. ( 28898989 )
2017
32
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2017
33
Primary Intraosseous Malignant Peripheral Nerve Sheath Tumor of Metacarpal Bones of the Hand in a Patient Without Neurofibromatosis 1: Report of a Rare Case. ( 28900340 )
2017
34
Spindle cell type malignant peripheral nerve sheath tumor arising in benign schwannoma with multiple intraosseous spinal metastasis: A case report. ( 28505957 )
2017
35
Hemisacrectomy with preservation of the contralateral sacral nerve roots and sacroiliac joint for pelvic neurofibrosarcoma in a 7-year-old child: case report with 2-year follow-up. ( 27689246 )
2017
36
Malignant peripheral nerve sheath tumor in children: A single-institute retrospective analysis. ( 29286874 )
2017
37
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 28558056 )
2017
38
Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. ( 29285213 )
2017
39
Acute hydrocephalus due to a primary malignant peripheral nerve sheath tumor of the cervicothoracic junction: A case report and review of the literature. ( 28502561 )
2017
40
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. ( 28124441 )
2017
41
Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. ( 27477693 )
2017
42
NF1(+/-) Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. ( 28646022 )
2017
43
Unusual primary breast cancer - malignant peripheral nerve sheath tumor: a case report and review of the literature. ( 28622765 )
2017
44
Malignant peripheral nerve sheath tumor of the vagus nerve: an uncommon cause of progressive dyspnea. ( 29307938 )
2017
45
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. ( 28534510 )
2017
46
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. ( 27875628 )
2017
47
Malignant Triton Tumor (Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation) Occurring in a Vascularized Free Flap Reconstruction Graft. ( 28387148 )
2017
48
Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. ( 28813519 )
2017
49
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. ( 28551330 )
2017
50
Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells. ( 28558025 )
2017

Variations for Neurofibrosarcoma

ClinVar genetic disease variations for Neurofibrosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh37 Chromosome 10, 111988034: 111988034
2 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh38 Chromosome 10, 110228276: 110228276

Expression for Neurofibrosarcoma

Search GEO for disease gene expression data for Neurofibrosarcoma.

Pathways for Neurofibrosarcoma

Pathways related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 NF1 NF2

GO Terms for Neurofibrosarcoma

Biological processes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.33 MXI1 NF1 NF2
2 negative regulation of cell migration GO:0030336 9.32 NF1 NF2
3 negative regulation of protein kinase activity GO:0006469 9.26 NF1 NF2
4 negative regulation of MAPK cascade GO:0043409 8.96 NF1 NF2
5 negative regulation of cell-matrix adhesion GO:0001953 8.62 NF1 NF2

Sources for Neurofibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....